Express Pharma

AUGUST 8, 2024

Additionally, when compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs. At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

Express Pharma

OCTOBER 25, 2023

Keytruda is an immunotherapy that works with the immune system to help fight cancer cells. It is different from chemotherapy or radiation therapy. The immune system sends certain types of cells called T-cells throughout your body to detect and fight infections and diseases—including cancer.

Immunity 105

Immunity Immunization Chemotherapy 105

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunity 98

Immunity Immunization Chemotherapy 98

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy 98

Chemotherapy Immunity Immunization 98

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 124

Chemotherapy Immunity Immunization 124

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy 116

Chemotherapy Immunity Immunization 116

Pharmacy Times

DECEMBER 11, 2024

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Immunity 52

Immunity Immunization Chemotherapy 52

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity 105

Immunity Immunization Chemotherapy Hospitals 105

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

Chemotherapy 96

Chemotherapy Immunity Immunization Hospitals 96

Pharmacy Times

JANUARY 24, 2025

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Chemotherapy 48

Chemotherapy Immunity Immunization 48

Pharmacy Times

DECEMBER 19, 2022

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity 98

Immunity Immunization Chemotherapy 98

Express Pharma

MARCH 17, 2025

This programme aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours akin to the well-established PD-1/PD-L1 blockade.

Immunity 66

Immunity Immunization Chemotherapy 66

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. New clinical data has shown a potential best-in-class next-generation antibody-drug conjugate (ADC) can offer promising response rates in extensive-stage small cell lung cancer.

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines 98

Vaccines Immunity Immunization Chemotherapy 98

European Pharmaceutical Review

AUGUST 2, 2024

The approval means TECELRA is indicated for individuals who: have received prior chemotherapy are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive have a tumour that expresses the MAGE-A4-antigen The FDA’s decision was based on results of the Phase II SPEARHEAD-1 (Cohort 1) trial.

Chemotherapy 98

Chemotherapy Immunity Immunization 98

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunity 111

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunity Immunization Hospitals 116

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Cancer Ther. 2020; 19(10): 2044–56.

Immunity 98

Immunity Immunization Chemotherapy 98

pharmaphorum

JANUARY 26, 2022

“Every year in the US, hundreds of people are diagnosed with metastatic uveal melanoma who, until now, had no approved treatment options,” said Immunocore chief executive Bahija Jallal.

Chemotherapy 124

Chemotherapy Labelling Immunity Immunization 124

Express Pharma

FEBRUARY 21, 2024

There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). GlobalData estimates the drug to earn $3.12 billion by 2029. “ Notably, the non-squamous patient subset had a median PFS of 5.6 months vs. 3.7

Chemotherapy 111

Chemotherapy Labelling Immunity Immunization 111

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. About the interviewee.

Immunity 105

Immunity Immunization Chemotherapy Compounding 105

pharmaphorum

JULY 20, 2022

The study compared VB-111 plus paclitaxel chemotherapy to paclitaxel given on its own, but showed no significant difference between the two groups, with PFS and OS in both coming in at just over five months and 13 months, respectively. .”

Chemotherapy 98

Chemotherapy Immunity Immunization 98

NY Times

MARCH 31, 2021

A drug that unleashes the immune system offers a rare glimmer of hope for those with a cancer that resists most treatments.

Immunity 83

Immunity Immunization Chemotherapy 83

Pharmafile

JANUARY 27, 2023

The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients. read more

Chemotherapy 52

Chemotherapy Immunity Immunization Communication 52

pharmaphorum

DECEMBER 30, 2021

Teclistamab binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour. Ultimately, the aim is to extend the time to relapse and prevent tumour resistance developing, in the hopes of effecting a functional cure for the cancer in more patients.

Chemotherapy 122

Chemotherapy Immunity Immunization 122

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

Chemotherapy 52

Chemotherapy Labelling Immunity Immunization 52

pharmaphorum

DECEMBER 21, 2020

Data from trials of the drug wowed ESMO in September – Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies. months, compared with 6.7

Biosimilars 126

Biosimilars Chemotherapy Immunity Immunization 126

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

pharmaphorum

MARCH 30, 2022

The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.

Chemotherapy 97

Chemotherapy Immunity Immunization 97

Pharmaceutical Technology

JANUARY 17, 2023

It could be used for T-Cell Acute Lymphoblastic Leukaemia (T-ALL) treatment in patients for whom bone marrow transplantation and chemotherapy failed to work. CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells.

Hospitals 110

Hospitals Chemotherapy Communication Immunity 110

Pharmaceutical Technology

JULY 8, 2022

Xenetic has obtained exclusive intellectual property licence for usage of DNases in oncology including systemic co-administration of DNases along with standard treatments, such as chemotherapy, radiation and checkpoint inhibitors, or in combination with standard chimeric antigen receptor (CAR) T therapies.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

pharmaphorum

NOVEMBER 29, 2022

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blockings its interactions with both PD-1 and B7.1 Patients given the Tecentriq plus chemotherapy combination survived a median of 16 months after treatment, compared with 13.4

Chemotherapy 52

Chemotherapy Immunity Immunization 52

European Pharmaceutical Review

OCTOBER 19, 2023

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. What do you envision the future of radiopharmaceuticals to be like?

Chemotherapy 105

Chemotherapy Compounding Immunity Immunization 105

Pharmaceutical Technology

SEPTEMBER 13, 2022

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. month progression-free survival (PFS) benefit over SOC chemotherapy. MSI-H/dMMR CRC accounts for 10-15% of all CRC.

Immunity 69

Immunity Immunization Chemotherapy 69

pharmaphorum

JUNE 7, 2021

The antibody blocks CD70, an immune checkpoint, and is designed to kill malignant cells by activating the immune system against them. Since then however the programme has generated some disappointing clinical results, including follow-up results from the phase 1/2 CULMINATE trial announced earlier this year.

Chemotherapy 64

Chemotherapy Immunity Immunization 64